Primary care app engagement was limited, with differences by substance type

Real-world use of digital therapeutics for substance use disorders in primary care: Observational study of the engagement cascade by substance type.

Drug and alcohol dependence โ€ข โ€ข Observational โ€ข Moderately Relevant
๐Ÿค–

AI Summary

This observational study examined engagement with FDA-authorized digital treatments for substance use disorder among 83 primary care patients prescribed reSET or reSET-O. The researchers compared engagement across patients identified as having unhealthy alcohol, cannabis, or other drug use. The primary outcome was progression through four app-use milestones, from activation to vendor-defined treatment completion.

Overall, 50.6% activated the app, 45.8% completed the user guide, 38.6% completed at least one module, and 13.3% met the treatment-completion criterion. Engagement was concentrated early: among app activators, half of module users stopped by week 4. Unhealthy alcohol use was associated with higher odds of several engagement milestones, while cannabis and other drug use were not associated with them. These observational findings cannot establish why engagement differed or whether the digital treatments improved health outcomes; this is an abstract-based summary, and the authors call for further research to validate the results.

๐Ÿ’ก Key Findings

1
Among 83 patients, 13.3% met the vendor-defined treatment-completion criterion.
High
99%
2
Engagement was concentrated early; half of module users stopped by week 4.
High
99%
3
Unhealthy alcohol use was associated with higher odds of app activation, guide completion, and completing at least one module; cannabis and other drug use were not associated with engagement milestones.
High
98%

๐Ÿ“„ Original Abstract

BACKGROUND: Patient engagement with digital therapeutics for substance use disorder (SUD) in primary care remains poorly understood. We analyzed engagement in routine care and whether specific types of substance use are associated with greater engagement. METHODS: This real-world observational study analyzed 83 primary care patients prescribed reSETยฎ or reSET-Oยฎ, US Food and Drug Administration-authorized digital therapeutics for SUD. Substance types (unhealthy alcohol, cannabis, and other drug use) were identified from routine health screens and clinical diagnoses. The primary outcome was progression through four engagement cascade milestones: app activation, user guide completion, completion of โ‰ฅโ€‰ one module, and treatment completion. Vendor logfiles provided weekly module counts. Logistic regression evaluated associations between substance use and engagement, adjusting for age and sex. RESULTS: Overall, 50.6% of patients activated the app, 45.8% completed the guide, 38.6% completed โ‰ฅโ€‰ one module, and 13.3% met the vendor-defined treatment completion criterion. Among those who activated it, the median number of modules completed was 4 (interquartile range 1-32); half of module users stopped by week 4. Unhealthy alcohol use was associated with higher odds of app activation, user guide completion, and completion of โ‰ฅโ€‰ one module (adjusted odds ratios [95% confidence intervals] = 2.84 [1.10-7.66], 3.48 [1.32-9.82], and 3.67 [1.32-11.26], respectively). Cannabis and other drug use were not associated with engagement milestones. CONCLUSIONS: Engagement with prescription-based digital therapeutics in primary care varies by substance type and is concentrated in the first month of use. Overall, engagement remains limited. Future research should validate these findings and refine engagement strategies.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.